Chester County News and Community Website
BERWYN, PA — AscellaHealth has introduced its latest Specialty & Rare Pipeline Digest™, a quarterly publication designed to provide stakeholders with comprehensive insights into current and upcoming specialty and rare …
AscellaHealth Launches Specialty & Rare Pipeline Digest to Guide Pharmaceutical Stakeholders Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently released a draft guidance in collaboration with the Office for Human Research Protections, outlining recommendations for including tissue biopsies in …
FDA Issues Draft Guidance on Tissue Biopsies in Clinical Trials Read More
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has unveiled the Savara Early Access Program, a significant initiative aimed at providing molgramostim to patients suffering from autoimmune pulmonary alveolar proteinosis (aPAP). This …
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment Read More
HEREFORD, PA — 20/15 Visioneers and Sravathi AI have announced a strategic partnership to introduce Sravathi AI’s advanced drug discovery platform to the North American market. This collaboration aims to revolutionize …
20/15 Visioneers Partners with Sravathi AI to Launch AI-Driven Drug Discovery Solutions in North America Read More
PHILADELPHIA, PA — Rohit Kulkarni is carving out a name for himself in the pharmaceutical sector. His innovative approach to data product management is significantly reshaping this industry. Kulkarni’s groundbreaking …
A Technological Revolution in Pharma: How Rohit Kulkarni is Redefining Drug Discovery through Data Read More
MALVERN, PA — YPrime has unveiled its latest innovation, the Tender Swollen Joint Count (TSJC) assessment. This tool is designed to revolutionize the way disease activity affecting joints is measured …
YPrime Introduces Innovative Assessment Tool to Enhance Clinical Trials for Autoimmune Diseases Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced a significant milestone in its Phase 1/2 …
Ocugen Advances in Pioneering Gene Therapy for Geographic Atrophy with DSMB Approval to Proceed to Medium Dose in Clinical Trial Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced a significant advancement in its ongoing clinical trial for Stargardt disease. The Data Safety and Monitoring Board (DSMB) for the …
Ocugen’s OCU410ST Advances in Clinical Trial for Stargardt Disease, Moving to Medium Dose Testing Read More